PMID- 20562528
OWN - NLM
STAT- MEDLINE
DCOM- 20150416
LR  - 20211020
IS  - 1942-0870 (Electronic)
IS  - 1942-0862 (Print)
IS  - 1942-0862 (Linking)
VI  - 2
IP  - 4
DP  - 2010 Jul-Aug
TI  - EB66 cell line, a duck embryonic stem cell-derived substrate for the industrial 
      production of therapeutic monoclonal antibodies with enhanced ADCC activity.
PG  - 405-15
LID - 12350 [pii]
AB  - Monoclonal antibodies (mAbs) represent the fastest growing class of therapeutic 
      proteins. The increasing demand for mAb manufacturing and the associated high 
      production costs call for the pharmaceutical industry to improve its current 
      production processes or develop more efficient alternative production platforms. 
      The experimental control of IgG fucosylation to enhance antibody dependent cell 
      cytotoxicity (ADCC) activity constitutes one of the promising strategies to 
      improve the efficacy of monoclonal antibodies and to potentially reduce the 
      therapeutic cost. We report here that the EB66 cell line derived from duck 
      embryonic stem cells can be efficiently genetically engineered to produce mAbs at 
      yields beyond a 1 g/L, as suspension cells grown in serum-free culture media. 
      EB66 cells display additional attractive grown characteristics such as a very 
      short population doubling time of 12 to 14 hours, a capacity to reach very high 
      cell density (> 30 million cells/mL) and a unique metabolic profile resulting in 
      low ammonium and lactate accumulation and low glutamine consumption, even at high 
      cell densities. Furthermore, mAbs produced on EB66 cells display a naturally 
      reduced fucose content resulting in strongly enhanced ADCC activity. The EB66 
      cells have therefore the potential to evolve as a novel cellular platform for the 
      production of high potency therapeutic antibodies.
FAU - Olivier, Stephane
AU  - Olivier S
AD  - VIVALIS;France.
FAU - Jacoby, Marine
AU  - Jacoby M
AD  - VIVALIS;France.
FAU - Brillon, Cedric
AU  - Brillon C
AD  - VIVALIS;France.
FAU - Bouletreau, Sylvana
AU  - Bouletreau S
AD  - VIVALIS;France.
FAU - Mollet, Thomas
AU  - Mollet T
AD  - VIVALIS;France.
FAU - Nerriere, Olivier
AU  - Nerriere O
AD  - VIVALIS;France.
FAU - Angel, Audrey
AU  - Angel A
AD  - VIVALIS;France.
FAU - Danet, Severine
AU  - Danet S
AD  - VIVALIS;France.
FAU - Souttou, Boussad
AU  - Souttou B
AD  - VIVALIS;France.
FAU - Guehenneux, Fabienne
AU  - Guehenneux F
AD  - VIVALIS;France.
FAU - Gauthier, Laurent
AU  - Gauthier L
AD  - Innate-Pharma; France.
FAU - Berthome, Mathilde
AU  - Berthome M
AD  - IRT1 INSERM U892;France.
FAU - Vie, Henri
AU  - Vie H
AD  - IRT1 INSERM U892;France.
FAU - Beltraminelli, Nicola
AU  - Beltraminelli N
AD  - VIVALIS;France.
FAU - Mehtali, Majid
AU  - Mehtali M
AD  - VIVALIS;France.
LA  - eng
PT  - Journal Article
DEP - 20100701
PL  - United States
TA  - MAbs
JT  - mAbs
JID - 101479829
RN  - 0 (Antibodies, Monoclonal)
RN  - 28RYY2IV3F (Fucose)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/chemistry/*therapeutic use
MH  - Antibody-Dependent Cell Cytotoxicity/genetics
MH  - Cell Growth Processes
MH  - Cell Line
MH  - Drug Industry/*methods
MH  - Ducks
MH  - *Embryonic Stem Cells
MH  - Fucose/*chemistry/metabolism
MH  - Genetic Engineering
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Quality Improvement
MH  - Stem Cells/metabolism
PMC - PMC3180087
EDAT- 2010/06/22 06:00
MHDA- 2015/04/17 06:00
PMCR- 2011/07/01
CRDT- 2010/06/22 06:00
PHST- 2010/06/22 06:00 [entrez]
PHST- 2010/06/22 06:00 [pubmed]
PHST- 2015/04/17 06:00 [medline]
PHST- 2011/07/01 00:00 [pmc-release]
AID - 12350 [pii]
AID - 1942-0862-2-4-6 [pii]
AID - 10.4161/mabs.12350 [doi]
PST - ppublish
SO  - MAbs. 2010 Jul-Aug;2(4):405-15. doi: 10.4161/mabs.12350. Epub 2010 Jul 1.